Pharmacologic options for CNS infections caused by resistant Gram-positive organisms. Expert Rev Anti Infect Ther 2008 Feb;6(1):83-99
Date
02/07/2008Pubmed ID
18251666DOI
10.1586/14787210.6.1.83Scopus ID
2-s2.0-40649123588 (requires institutional sign-in at Scopus site) 15 CitationsAbstract
Infectious disease continues to evolve, presenting new and challenging clinical situations for practitioners. Specific to device-related and neurosurgical-related CNS infections, Gram-positive organisms are of growing concern. Current Infection Disease Society of America guidelines for the treatment of CNS infections offer little direction after conventional therapy, consisting of vancomycin, has failed or the patient has demonstrated intolerance. A review of literature evaluating alternative therapies, specifically linezolid, quinupristin/dalfopristin, daptomycin and tigecycline, will be presented. Interpretations of these data are offered followed by a brief presentation of future therapies, including ortavancin, telavancin, dalbavancin, ceftobiprole and iclaprim, all of which possess potent Gram-positive activity.
Author List
Peppard WJ, Johnston CJ, Urmanski AMAuthor
William J. Peppard PharmD Trauma/Surgical Critical Care Pharmacist in the Pharmacy department at Froedtert HospitalMESH terms used to index this publication - Major topics in bold
AnimalsAnti-Bacterial Agents
Central Nervous System Infections
Drug Resistance, Multiple, Bacterial
Drugs, Investigational
Gram-Positive Bacterial Infections
Humans
